At diagnosis, substantial heterogeneity has been observed within the putative LSC population in the bone marrow of CML patients, and the concentration of CD26+ LSCs correlates with TKI resistance [43]. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.